Although the epidemic situation of China’s new coronary pneumonia has been greatly improved, and everyone has basically returned to normal life and work, the epidemic situation abroad is still extremely serious. The latest WHO statistics show that 215 countries and regions have reported a total of 4049800 confirmed cases of new coronary pneumonia, an increase of more than 89,000 cases over the same period yesterday, a daily increase of 2.5%. The cumulative deaths of patients with new coronary pneumonia worldwide exceeded 270,000, reaching 276,600, with an average mortality rate of 7%. It is still unpredictable when the global new crown epidemic will be effectively controlled. Among the drugs for treating new coronary pneumonia, Academician Zhong Nanshan made a deafening voice: I have confidence and evidence that Lianhua Qingwen is really effective. The team of academician Zhong Nanshan conducted an in vitro cell test on Lianhua Qingwen Capsule, and the test results showed that the drug has a weak inhibitory effect on the virus, but it has a good repair effect on the cell damage caused by the virus. Lianhua Qingwen Capsule is more suitable for patients with common new-type coronary pneumonia, and 80% of patients with new-type coronary pneumonia are common patients. Academician Zhang Boli also introduced that the clinical research results showed that the patients who took Lianhua Qingwen Capsule had better disappearance rate of the main clinical symptoms and the duration of clinical symptoms, and the improvement of lung imaging reached 83.8%. The clinical cure rate reached 78.9%. Lianhua Qingwen Capsule is actually an old medicine, originally a patented Chinese medicine developed during the SARS period. In 2003, the SARS epidemic spread and there was no effective treatment in China at that time. Therefore, the R & D team of the pharmaceutical company used the experience of Chinese medical doctors to treat exogenous fever, such as “Ma Xing Shi Gan Decoction” in Zhang Zhongjing’s “Treatise on Febrile Diseases” in the Han Dynasty “,” Yinqiaosan “in” Diagnosis of Warm Diseases “in the Qing Dynasty, and the use of” rhubarb “in the” The Plague Theory “in the Ming Dynasty, formed the basic formula of Lianhua Qingwen. The results of the Lianhua Qingwen anti-SARS virus test carried out by the laboratory of the Academy of Military Medical Sciences at that time were exciting. After the outbreak of pandemic influenza in 2009, a number of research institutes and national key laboratories conducted research on Lianhua Qingwen and found that it was effective against H1N1, H3N2, H9N2, H7N9, influenza B virus, coronavirus, respiratory syncytial virus, rhinovirus , Herpes virus, Coxsackie virus has an inhibitory effect, that is to say Lianhua Qingwen has a broad-spectrum antiviral effect. Chinese medicine has a long history of anti-epidemic. In the view of Chinese medicine, influenza, SARS, and New Coronary Pneumonia all belong to the category of “external fever”, which is what Chinese medicine calls “the plague.” Lianhua Qingwen contains 13 kinds of Chinese medicines such as forsythia, honeysuckle, ephedra, fried bitter almond, gypsum, Radix isatidis, Houttuynia cordata, patchouli, rhubarb, Rhodiola, menthol, licorice, etc. It has the effects of clearing away detoxification and detoxifying the lungs. The theory of TCM syndrome differentiation and treatment is very esoteric and cannot be understood by medical experts from European and American countries that are mainly “Western medicine”. Recently, foreign media reported that “Swedish Customs Laboratories tested the anti-new crown Chinese medicine Lianhua Qingwen, which was advocated by China, claiming that its ingredient“ only menthol ”is ineffective against new crown pneumonia. This is a complete rumor. “Lianhua Qingwen for the treatment of new coronavirus (2019-nCoV) pneumonia network pharmacology research and preliminary evidence” published in the magazine, selected 378 Lianhua Qingwen active ingredients, and the target of response to the new coronavirus reached 55 Therefore, Lianhua Qingwen’s prevention and treatment of new coronary pneumonia is not only reflected in the characteristics of its prescriptions, but pharmacological studies have also confirmed that the drug acts on the target of the virus through a variety of active ingredients, thereby exerting a therapeutic effect, so the drug is impossible There are only menthol ingredients. Through the media and reports, we can see that Lianhua Qingwen has been registered in Thailand, Brazil, Indonesia, Canada, Mozambique, Romania, Singapore and other countries. It is undoubtedly that for Chinese medicine to go abroad Good and affirmative. The control of infectious diseases can still only be based on eliminating the source of infection and cutting off the transmission route. The representative is Lianhua Qingwen Traditional Chinese medicine has been widely used and highly evaluated in domestic epidemic prevention and control. It is also hoped that traditional Chinese medicine can make a certain contribution to the global new crown epidemic and let the world know the value of the motherland’s medicine.